Prodrug design, synthesis and pharmacokinetic evaluation of (3′R, 4′R)-3-hydroxymethyl-4-methyl-3′, 4′-di-O-(S)-camphanoyl-(+)-cis-khellactone

Prodrug design, synthesis and pharmacokinetic evaluation of (3′R, 4′R)-3-hydroxymethyl-4-methyl-3′, 4′-di-O-(S)-camphanoyl-(+)-cis-khellactone

3-Hydroxymethyl-4-methyl-DCK (3, HMDCK) was discovered previously as a potent HIV non-nucleoside reverse transcriptase inhibitor (NNRTIs) (EC50: 0.004 μM, TI: 6225) with a novel mechanism of action. It exerts anti-HIV activity by inhibiting the production of HIV-1 double-stranded viral DNA from a si...

Full description

Bibliographic Details
Main Authors: Huanfang Guo, Xiaomei Zhuang, Keduo Qian, Lianqi Sun, Xiaofeng Wang, Hua Li, Kuohsiung Lee, Lan Xie
Format: Article
Language:English
Published: Elsevier 2012-04-01
Series:Acta Pharmaceutica Sinica B
Subjects:
3-Hydroxymethyl-4-methyl-DCK
Synthesis
Pharmacokinetic
Prodrug
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383512000317

Internet

http://www.sciencedirect.com/science/article/pii/S2211383512000317

Similar Items